Susan is a financial and accounting leader with more than 25 years of diverse experience strengthening corporate financial strategy, efficiencies, and controls. She’s been an integral part of Melinta’s financial and accounting team since 2016 and has served as CFO since April 2021.

In April 2024, Susan was appointed to the Board of Directors for BiomX, a public, clinical-stage company pioneering natural and engineered phage cocktails and personalized treatments to combat bacteria in chronic diseases. Susan brings her financial expertise to this role, serving as a member and chair of the audit committee.

Before joining Melinta, Susan served as Corporate Controller at Textura, where she oversaw the accounting function and played a lead IPO role with responsibility for centralizing accounting functions post-acquisition. Before Textura, she held leadership roles at Orbitz Worldwide, Inc., where she directed global technical accounting processes. And before that, Susan managed the SEC reporting and revenue functions at Facet Biotech and PDL BioPharma.

Susan began her career in public accounting at Ernst & Young, where she worked with a diverse client base ranging from large, public international SEC engagements to development-stage enterprises.

She holds a B.S. in Business Commerce, concentration in Accounting, from Santa Clara University and is a certified public accountant.

Jennifer is a seasoned life sciences industry executive with demonstrated success in general management, legal, and compliance.

Before Melinta, Jennifer held several leadership roles at The Medicines Company. She led legal and compliance counsel for multiple business units guiding commercial, medical, market access, and regulatory activities in those roles

Before The Medicines Company, Jennifer was an attorney at Porzio, Bromberg & Newman, P.C., a law firm specializing in the life sciences industry. She advised pharmaceutical, medical device, and biotech companies on a variety of legal, regulatory, and compliance issues.

Jennifer holds a B.A. in History, magna cum laude, from New York University and a J.D. from the Rutgers School of Law, where she was managing editor of the Rutgers Law Review.

John Harlow is a pharmaceutical-industry executive with commercial, marketing, and sales leadership expertise. He has led multiple successful initiatives that have launched or relaunched pharma companies ranging from start-ups to large-sized companies. His work also includes transformative organizational development for internal teams.

Before joining Melinta, John was the Chief Commercial Officer at Baudax Bio where he led the launch of a non-opioid and post-operative pain treatment for hospitals and acute care settings. Prior to that role, he held executive positions at RecroPharma, Endo Pharmaceuticals, and Shionogi, Inc.

John graduated with high honors in Biology from Lehigh University and completed his Masters in Business Administration in Pharmaceutical Management & Marketing at Seton Hall University.

Kristen Allgor is a seasoned human resources executive with a proven track record of leading organizations through change and building high-performing teams. Previously, Kristen served as the Vice President of Human Resources at Allergan for seven years. At Allergan, she held various roles including business partner to the commercial, finance and technology teams. In this capacity, she led teams through multiple mergers and acquisitions and implemented a global compensation platform for the company.

Prior to Allergan, Kristen held executive human resources roles at Bausch Health, Pfizer, Virgin Mobile and PepsiCo. In these roles, she focused on implementing best-in-class compensation and benefit programs.

Kristen holds a B.A. in Psychology from Western Michigan University and a M.A. in
Human Resources from Michigan State University.